Form 4: iRhythm CCO Sells Shares via 10b5-1 Plan
Insider Trading Report
iRhythm Technologies' Chief Commercial Officer, Chad Patterson, sold 2,555 shares of common stock for $158.97 per share, executed under a pre-established Rule 10b5-1 trading plan.
Summary
- Chad Patterson, Chief Commercial Officer of iRhythm Technologies, Inc. (IRTC), reported a sale of company common stock.
- On August 6, 2025, Patterson disposed of 2,555 shares at a price of $158.97 per share.
- The transaction was executed under a Rule 10b5-1 trading plan, which was established on November 25, 2024.
- Following this transaction, Patterson beneficially owns 43,667 shares of iRhythm Technologies common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly negative. While an insider sale can be perceived negatively, the fact that it's under a 10b5-1 plan mitigates concerns, suggesting a pre-planned liquidity event rather than a lack of confidence in the company's future.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not a reaction to recent negative company developments.
Negatives
- An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.
Industry Context
This insider transaction is a routine disclosure for publicly traded companies in the medical device and healthcare technology sector, reflecting an officer's pre-planned stock sale rather than a strategic industry move.
Stakeholder Impact
- Shareholders may note the reduction in insider ownership, though the 10b5-1 plan context suggests it's a routine event.
Key Dates
| Date | Description |
|---|---|
| 11/25/2024 | Date Rule 10b5-1 trading plan was established by Chad Patterson. |
| 08/06/2025 | Date of common stock transaction (sale of 2,555 shares). |
| 08/07/2025 | Date the Form 4 was signed by attorney-in-fact Marc Rosenbaum. |
Recommendation
holdThis filing is a routine insider transaction (Form 4) indicating a pre-scheduled sale under a 10b5-1 plan. This type of transaction typically does not signal new material information about the company's performance or outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
iRhythm Technologies, IRTC, Form 4, Insider Sale, Chad Patterson, 10b5-1 Plan, Stock Transaction, Officer Sale, Medical Devices, Healthcare Technology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.